Company news

Gb Sciences, Inc. (OTC:GBLX) news

Gb Sciences, Inc. news releases on 6ix. Latest, Dec 22, 2022: Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based…

Gb Sciences, Inc. (OTC:GBLX) news

Press releases & updates

Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform

Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations

Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients

TODAY: Gb Sciences' President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit

Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

TODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference

Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease

TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article

Gb Sciences is Leading Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™

Gb Sciences Leads Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™

TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containing Formulations for Parkinson's Disease at 2022 NeuroForum Summit

TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit

TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference

FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences' COVID-19-Related, Anti-Inflammatory Therapies

Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge

Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article

UPDATE: Gb Sciences Issues Shareholder Letter

Gb Sciences Issues Summary Shareholder Letter

Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis

Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment

Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility

Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives

Gb Sciences Accelerates Drug Development via Innovative Biopharma Technology and Strategic Partnerships

Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety

Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation

Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference

Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021

Gb Sciences to Present at the SNN Network Summer Virtual Event on Wednesday, August 18th, 2021

GB Sciences Is Developing Plant-Inspired Mixtures for Anxiety, Depression, and Pain From PhAROS, GB Sciences' Proprietary AI-Accelerated Drug Discovery Platform

GB Sciences Using AI Technology in Plant-Based Drug Discovery Research

GB Sciences' Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President

GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals

GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platform

GB Sciences Publishes Study on Creation of Novel Terpene-Containing Nanoparticles for Pain Relief

GB Sciences Announces Issuance of US Patent for its Proprietary, Cannabinoid-Based Anti-Inflammatory Formulations

GB Sciences Files Provisional Patent Application for the Treatment of Chronic Inflammation Utilizing Its Novel Cannabinoid Containing Complex Mixtures (CCCM)

GB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome (ARDS), the Leading Cause of Hospitalization and Deaths, Utilizing Its Cannabinoid Containing Complex Mixtures (CCCM(TM))

GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson's Disease Cannabinoid Formulations and Begins Mechanism of Action Study With the National Research Council of Canada

GB Sciences Announces Outstanding Results from Preclinical Study of Its Parkinson's Disease Formulations

GB Sciences Announces the Sale of The Majority Interest in Nevada Cultivation Operations to Focus on Its First Two Cannabinoid-Based Medical Compounds for Parkinson's Disease and Neuropathic Pain

GB Sciences Closes the Sale of GB Sciences Louisiana Cannabis Business to Wellcana Plus and Retains the Benefit of IP Developed Under GB Sciences Louisiana's Master Research and Development Agreement

The Closing Date of GB Sciences' Sale of GB Sciences Louisiana LLC Is Delayed

GB Sciences Welcomes Esteemed Patent and Intellectual Property Attorney, Mr. Edmond DeFrank, to Its Board of Directors

GB Sciences' Chief Science Officer Featured on the Cover of the Marijuana Business Magazine

GB Sciences Sells Its Louisiana Medical Marijuana Business At A $32 Million Total Valuation

U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers

GB Sciences Names Darin Carpenter as Executive Vice President of Cannabis Operations

GB Sciences Prepares To Launch New Products In Louisiana With Educational Seminars For Doctors And Pharmacists

History Made! GB Sciences Louisiana Announces Medical Cannabis Products Now for Sale for First Time in State History

GB Sciences Files Novel Patent Application For Chronic Pain Treatments Based On Proprietary Cannabis-Derived Formulations